The challenge of multidrug resistance: Actual strategies in the development of novel antibacterials

Applied Microbiology and Biotechnology

Volumn 63, Issue 4, 2004, Pages 335-343

  Schmidt, F R ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ARSPHENAMINE; BACITRACIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CATHELICIDIN; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; DALFOPRISTIN; DERMASEPTIN; ERYTHROMYCIN DERIVATIVE; GLYCOPEPTIDE; KETOLIDE; LINEZOLID; MACROLIDE; NALIDIXIC ACID; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PRISTINAMYCIN; PROTEGRIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN DERIVATIVE; STREPTOMYCIN; SULFONAMIDE; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTICS; DRUG DEVELOPMENT; DRUG RESISTANCE;

ANTIMICROBIAL ACTIVITY; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BIOTECHNOLOGY; DIAGNOSTIC PROCEDURE; DRUG POTENCY; DRUG STRUCTURE; EXTRACELLULAR SPACE; HEMOLYSIS; HUMAN; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULE; MULTIDRUG RESISTANCE; NONHUMAN; PATHOGENESIS; SCALE UP; SCREENING; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL PHYSIOLOGY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOMICS; PEPTIDES; PROTEOMICS;

BACTERIA (MICROORGANISMS);

EID: 1642496906     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00253-003-1344-1     Document Type: Short Survey

References (110)

1. Ali RS, Falconer A, Ikram M, Bissett CE, Cerio R, Quinn AG (2001) Expression of the peptide antibiotics human beta defensin 1 and human beta defensin 2 in normal human skin. J Invest Dermatol 117:106-111
2. Aretz W, Meiwes J, Seibert G, Vobis G, Wink J (2000) Friulimicins: novel lipopetide antibiotics with peptidoglycan synthesis inhibiting activity from Actinoplanes friulensis sp. Nov. I. Taxonomic studies of the producing microorganism and fermentation. J Antibiot 53:807-815
3. Arroyo M, de la Mata I, Acebal C, Castillon MP (2003) Biotechnological application of penicillin acylases: state of the art. Appl Microbiol Biotechnol 60:507-514
4. Bandak, SI, Tumak MR, Allen BS, Bolzon LD, Preston DA (2000) Assessment of the susceptibility of Streptococcus pneumoniae to cefaclor and loracarbef in 13 countries. J Chemother 12:299-305
5. Bauer F, Schweimer K, Kluver E, Conejo-Garcia I, Forssmann W, Rosch P, Adermann K, Sticht H (2001) Structure determination of human and murine beta defensins reveal structural conservation in the absence of significant sequence similarity. Protein Sci 10:2470-2479
6. Bax R, Mullan N, Verhoef J (2000) The millennium bugs-the need for and development of new antibacterials. Int J Antimicrob Agents 16:51-59
7. Bechinger B (2001) Solid state NMR investigations of interaction contributions that determine the alignment of helical polypeptides in biological membranes. FEBS Lett 504:161-165
8. Blondelle SE (2001) Synthetic combinatorial libraries: an emerging approach toward the identification of novel antibiotics. In: Lohner K (ed) Development of novel antimicrobial agents: emerging strategies. Horizon, Wymondham, Norfolk, UK, pp 199-216
9. Blondelle SE, Lohner K (2000) Combinatorial libraries: a tool to design antimicrobial and antifungal peptides analogues having lytic specificities for structure-activity relationship studies. Biopolymers 55:74-87
10. Blondelle SE, Takahashi E, Houghten RA, Perez-Paya E (1996) Rapid identification of compounds having enhanced microbial activity using conformationally defined combinatorial libraries. Biochem J 313:141-147
11. Boeck LD, Wetzel RW (1990) A54145, a new lipopeptide antibiotic complex: factor control through precursor-directed biosynthesis. J Antibiotics 43:607-615
12. Boeck LD, Papiska HR, Wetzel RW, Mynderse JS, Fukuda DS, Mertz FP, Berry DM (1990) A54145, a new lipopeptide antibiotic complex: discovery, taxonomy, fermentation and HPLC. J Antibiotics 43:587-593
13. Bonnefoy A, Guitton M, Delachaume C, Le Priol P, Girard AM (2001) In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models. Antimicrob Agents Chemother 45:1688-1692
14. Branny P, Pearson JP, Everett CP, Köhler T, Iglewski BH, van Delden C (2001) Inhibition of quorum sensing by a Pseudomonas aeruginosa dksA homologue. J Bacteriol 183:1531-1539
15. Breukink E, Wiedemann I, Van Kraaij C, Kuipers OP, Sahl HG, De Kruijff (1999) Use of the cell wall precursor lipid II by pore forming peptide antibiotic. Science 286:2361-2364
16. Bryson HM, Spencer CM (1996) Quinupristin-Dalfopristin. Drugs 52:406-415
17. Cane DE, Walsh CT (1999) The parallel and convergent universes of polyketide synthases and non-ribosomal peptide synthases. Chem Biol 6:R319-R325
18. Capobianco JO, Cao Z, Shortridge VD, Ma Z, Flamm RK, Zhong P (2000) Studies of the novel ketolide ABT-773: transport, binding to ribosomes and inhibition of protein synthesis in Streptococcus pneumoniae. Antimicrob Agents Chemother 44:1562-1567
19. Cassell GH (1997) Emergent antibiotic resistance: health risks and economic impact. FEMS Immunol Med Microbiol 18:271-274
20. Chadwick DJ, Goode J (1997) Antibiotic resistance: origins, evolution, selection and spread. Wiley, New York
21. Chalker AF, Lunsford RD (2002) Rational identification of new antibacterial drug targets that are essential for viability using a genomic based approach. Pharmacol Ther 95:1-20
22. Chopra I, Hodgson J, Metcalf B, Poste G (1997) The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antimicrob Agents Chemother 41:497-503
23. Coque TM, Tomayko JF, Ricke SC, Okhuysen PC (1996) Vancomycin resistant enterococci from nosocomial, community and animal sources in the United States. Antimicrob Agents Chemother 40:2605-2609
24. Cormican MG, Jones RN (1996) Emerging resistance to antimicrobial agents in Gram-positive bacteria. Drugs 51 Suppl 1:1-16
25. Costerton JW, Stewart PS (2001) Battling biofilms. Sci Am 285:74-81
26. Counter FT, Allen NE, Fukuda DS, Hobbs JN, Ott J, Ensminger PW, Mynderse JS, Preston DA, Wu, CYE (1990) A54145, a new lipopetide antibiotic complex: microbiological evaluation. J Antibiot 43:616-622
27. Cuzin M (2001) DNA-chips: a new tool for genetic analysis and diagnostics. Transfus Clin Biol 8:291-296
28. Du L, Shen B (2001) Biosynthesis of hybrid peptide-polyketide natural products. Curr Opin Drug Discov Dev 4:215-228
29. Du L, Sanchez C, Shen B (2001) Hybrid peptide-polyketide natural products: biosynthesis and prospects towards engineering novel molecules. Metab Eng 3:78-95
30. Entian KD, Klein C (1993) Lantibiotika, eine Klasse ribosomal synthetisierter Peptid-Antibiotika. Naturwissenschaften 80:454-460
31. Felmingham D, Zhanel G, Hoban D (2001) Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens. J Antimicrob Chemother 48:33-42
32. Fernandez-Lopez S, Kim HS, Choi EC, Delgado M, Granja JR, Khasanov A, Kraehenbuehl A, Long G, Weinberger DA, Wilcoxen KM, Ghadiri R (2001) Antibacterial agents based on the cyclic D,L-a-peptide architecture. Nature 412:452-455
33. Finch RG (1996) Antibacterial activity of Quinupristin/Dalfopristin. Drugs 51 [Suppl 1]:31-37
34. Floss HG (2001) Antibiotic synthesis: from natural to unnatural products. J Ind Microbiol Biotechnol 27:183-194
35. Gold HS, Moellering RC (1996) Antimicrobial drug resistance. Drug Therapy 335:1445-1453
36. Good AC, Krystek SR, Mason JS (2000) High throughput and virtual screening: core lead discovery technologies move towards integration: Drug Discov Today 5 [12 Suppl 1]:S61-S69
37. Hall RM, Collis CM (2001) Origins and evolution of antibiotic and multiple antibiotic resistance in bacteria. In: Lohner K (ed) Development of novel antimicrobial agents: emerging strategies. Horizon, Wymondham, Norfolk, UK, pp 17-30
38. Hancock REW, Patrzykat A (2002) Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord 2:79-83
39. Hancock REW, Rozek A (2002) Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol Lett 10:143-149
40. Hancock REW, Scott MG (2000) The role of antimicrobial peptides in animal defences. Proc Natl Acad Sci USA 97:8856-8861
41. Haney SA, Alksne LE, Dunman PM, Murphy E, Projan SJ (2002) Genomics in anti-infective drug discovery-getting to an endgame. Curr Pharm Des 8:1099-1118
42. Heymann DL (2000) The urgency of a massive effort against infectious diseases. Statement before the United States House of Representatives. World Health Organisation, Geneva, Switzerland
43. Hiramatsu K (1998) The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med 104:7S-10S
44. Hiramatsu K, Hanaki K, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135-146
45. Hollingshead SK, Briles DE (2001) Streptococcus pneumoniae: new tools for an old pathogen. Curr Opin Microbiol 4:71-77
46. Höltje HD, Stoll F, Ghosh R, Stahl G, Höltje M (2002) New methods in drug research. Pharm Ind 64:838-843
47. Hutchinson CR, Fujii I (1995) Polyketide synthase gene manipulation : a structure-function approach in engineering novel antibiotics. Annu Rev Microbiol 49:201
48. Jouenne T, Mor A, Bonato H, Junter GA (1998) Antibacterial activity of synthetic dermaseptins against growing and non-growing E. coli cultures. J Antimicrob Chemother 42:87-90
49. Kaneda T (1977) Fatty acids of the genus Bacillus: an example of branched chain preference. Bacteriol Rev 41:391-418
50. Katz L, Donadio S (1993) Polyketide synthesis: prospects for hybrid antibiotics. Annu Rev Microbiol 47:875-912
51. Kleinkauf H, von Döhren H (1995) Linking peptide and polyketide biosynthesis. J Antibiot 48:563-567
52. Lay JO (2001) MALDI-TOF mass spectrometry of bacteria. Mass Spectrom Rev 20:172-194
53. Leclercq JV (1996) Epidemiology and control of multiresistant enterococci. Drugs 52:47-49
54. Leclercq R (2001) Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin. J Antimicrob Chemother 48:9-23
55. Lehrer RI, Ganz T (2002) Cathelicidins: a family of endogenous antimicrobial peptides. Curr Opin Hematol 9:18-22
56. Leuenberger HGW, Matzinger PK, Wirz B (1999) Synthesis and metabolism of drugs by means of enzyme catalysed reactions. Chimia 53:536-540
57. Lohner K, Staudegger E (2001) Are we on the threshold of the post-antibiotic era? In: Lohner K (ed) Development of novel antimicrobial agents: emerging strategies. Horizon, Wymondham, Norfolk, UK, pp 1-16
58. Mankelow DP, Neilan BA (2000) Non-ribosomal peptide antibiotics. Expert Opin Ther Pat 10:1583-1591
59. Marahiel MA, Stachelhaus T, Mootz HD (1997) Modular peptide synthases involved in nonribosomal peptide synthesis. Chem Rev 97:2651-2673
60. Martin JF (1998) New aspects of genes and enzymes for β-lactam antibiotic synthesis. Appl Microbiol Biotechnol 50:1-15
61. McDaniel R, Katz L (2001) Genetic engineering of novel macrolide antibiotics. In: Lohner K (ed) Development of novel antimicrobial agents: emerging strategies. Horizon, Wymondham, Norfolk, UK, pp 45-60
62. Miller MB, Bassler BL (2001) Quorum sensing in bacteria. Annu Rev Microbiol 55:165-199
63. Mor A (2000) Peptide-based antibiotics: a potential answer to raging antimicrobial resistance. Drug Dev Res 50:440-447
64. Mor A, Hani K, Nicolas P (1994) The venebrate peptide antibiotics dermaseptins have overlapping structural features but target specific organisms. J Biol Chem 269:31635-31641
65. Muhle SA, Tam JP (2001) Design of Gram-negative selective antimicrobial peptides. Biochemistry 40:5777-5785
66. Muhlemann K (2002) Mechanismen der Antibiotikaresistenz. Ther Umschau 59:5-10
67. Nicolaou KC, Boddy NC (2001) Behind enemy lines. Sci Am 284:46-53
68. Nielsen J (2001) Metabolic engineering. Appl Microbiol Biotechnol 55:263-285
69. Nilsson CL (2002) Bacterial proteomic and vaccine development. Am J Pharmacogenomics 2:59-65
70. Nissen-Meyer J, Nes IF (1997) Ribosomally synthesized antimicrobial peptides: their function, structure, biogenesis, and mechanism of action. Arch Microbiol 167:67-77
71. Pankuch GA, Visalli MA, Jacobs MR, Applebaum PC (1998) Susceptibilities of penicillin and erythromycin susceptible and resistant Pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 42:624-630
72. Paul N, Rognan D (2002) ConsDock: a new program for the consensus analysis of protein-ligand interaction. Proteins Struct Funct Genet 47:521-533
73. Paulsen FP, Pufe T, Schaudig U, Held-Feindt J, Lehmann J, Schroder JM, Tillmann BN (2001) Detection of natural peptide antibiotics in human nasolacrimal ducts. Invest Ophthalmol Vis Sci 42:2157-2163
74. Pechère JC (1996) Streptogramins. Drugs 51 [Suppl 1]:13-19
75. Pfeifer BA, Khosla C (2001) Biosynthesis of polyketides in heterologous hosts. Microbiol Mol Biol Rev 3:106-118
76. Rowe-Magnus DA, Davies J, Mazel D (2002a) Impact of integrons and transposons on the evolution of resistance and virulence. In: Hacker J, Kaper JB (eds) Pathogenicity islands and the evolution of pathogenic microbes. Springer, Berlin Heidelberg New York, pp 167-188
77. Rowe-Magnus DA, Davies J, Mazel D (2002b) Impact of integrons and transposons on the evolution of resistance and virulence. Curr Top Microbiol Immunol 264:167-188
78. Rudert F (2000) Genomics and proteomics tools for the clinic. Curr Opin Mol Ther 2:633-642
79. Rusinko A, Young SS, Drewry DH, Gerritz SW (2002) Optimization of focused chemical libraries using recursive partioning. Comb Chem High Throughput Screen 5:125-133
80. Saiman L, Tabibi S, Starner TD, San-Gabriel P, Winokur PL, Hong-Peng J, McCray PB, Tack BF (2001) Cathelicidin peptides inhibit multiply antibiotic resistant pathogens from patients with cystic fibrosis. Antimicrob Agents Chemother 45:2838-2844
81. Schmidt FR (2002) Beta-lactam antibiotics: aspects of manufacture and therapy. In: Osiewacz HD (ed) The Mycota, vol X: industrial applications. Springer, Berlin Heidelberg New York, pp 69-91
82. Sieradzki K, Tomasz A (1996) A highly vancomycin resistant laboratory mutant of Staphylococcus aureus. FEMS Microbiol Lett 142:161-166
83. Sperandio V, Torres AG, Giron JA, Kaper JB (2001) Quorum sensing is a global regulatory mechanism in enterohemorrhagic Escherichia coli O157:H7. J Bacteriol 183:5187-5197
84. Staunton J, Wilkinson B (2001) Combinatorial biosynthesis of polyketides and nonribosomal peptides. Curr Opin Chem Biol 5:159-164
85. Stephenson J (2001) Researchers describe latest strategies to combat antibiotic resistant microbes. JAMA 285:2317-2318
86. Sun C, Wang H, Sun B, Peng XX (2000) Progress in the study of peptide antibiotics. Chin Pharmacol Bull 16:605-609
87. Sundberg SA (2000) High-throughput and ultra-high-throughput screening: solution- and cell-based approaches. Curr Opin Biotechnol 11:47-53
88. Tally FP, DeBruin F (2000) Development of daptomycin for Grampositive infections. J Antimicrobial Chemotherapy 46:523-526
89. Tam JP, Lu YA, Yang YL (2002) Antimicrobial dendrimeric peptides. Eur J Biochem 269:923-932
90. Trauger JW, Walsh CT (2000) Heterologous expression in Escherichia coli of the first module of nonribosomal peptide synthase for chloroeremomycin, a vancomycin-type glycopeptide antibiotic. Proc Natl Acad USA 97:3112-3117
91. Trautmann M, Ruhnke M, Krsken M, Brauers J, Springsklee M, Marre R (1997) Quinupristin/Dalfopristin. Chemother J 6:31-42
92. Trnobranski PH (1998) Are we facing a "post-antibiotic era"? - a review of the literature regarding antimicrobial drug resistance. J Clin Nurs 7:392-100
93. Troxler R, von Grävenitz A, Funke G, Wiedemann B, Stock I (2000) Natural antibiotic susceptibility by Listeria species: L. grayi, L. innocua, L. ivanovii, L. monocytogenes, L. seeligeri and L. welshimeri strains. Clin Microbiol Infect 6:525-535
94. Vannuffel P, Cocito C (1996) Mechanism of action of streptogramins and macrolides. Drugs 51 [Suppl 1]:20-30
95. Versalovic J (2001) DNA-chip-based microbiology. Clin Microbiol Newslett 23:99-102
96. Vertesy, L, Aretz W, Decker H, Ehlers E, Kurz M, Schmidt FR, Knauf M, Kogler H (1999) Lipopetide calcium salts: process for their preparation and their use. European Patent 1068223
97. Vertesy L, Ehlers E, Kogler H, Kurz M, Meiwes J, Seibert G, Vogel M, Hammann P (2000) Friulimicins: novel lipopetide antibiotics with peptidoglycan synthesis inhibiting activity from Actinoplanes friulensis sp. nov. II. Isolation and structural characterization. J Antibiot 53:816-827
98. Waterman SR (2001) Bacterial genomics as a potential tool for discovering new antimicrobial agents. Am J Pharmacogenomics 1:263-269
99. Whittier S (2001) Update on the microbiology of cystic fibrosis: traditional and emerging pathogens. Clin Microbial Newslett 23:67-71
100. WHO Report on Infectious Diseases (2000) Overcoming antimicrobial resistance. World Health Organisation, Geneva, Switzerland
101. WHO Report on Infectious Diseases (2002) Scaling up the response to infectious diseases; a way out of poverty. World Health Organisation, Geneva, Switzerland
102. Wiedemann I, Breukink E, Van-Kraaij C, Kuipers OP, Bierbaum G, De Kruijff B, Sahl HG (2001) Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem 276:1772-1779
103. Wiesner A, Bogumi R (2002) Das ProteinChip-System in klinischer Forschung, Proteinisolierung und Proteinanalytik. Laborwelt, Biocom, April: 10-17
104. Williams RJ, Heymann DL (1998) Containment of antibiotic resistance. Science 279:1153-1154
105. World Health Reports (1996-2001) World Health Organisation, Geneva, Switzerland
106. Yan H, Hancock REW (2001) Synergistic interactions between mammalian antimicrobial defense peptides. Antimicrob Agents Chemother 45:1558-1560
107. Zaks A (2001) Industrial biocatalysis. Curr Opin Chem Biol 5:130-136
108. Zasloff M (2001) The commercial development of the antimicrobial peptide Pexiganan. In: Lohner K (ed) Development of novel antimicrobial agents: emerging strategies. Horizon, Wymondham, Norfolk, UK, pp 262-272
109. Zhu J, Miller MB, Vance RE, Dziejman M, Bassler BL, Mekalanos JJ (2002) Quorum-sensing regulators control virulence gene expression in Vibrio cholerae. Proc Natl Acad Sci USA 99:3129-3134
110. Zmijewski MJ, Briggs B, Occolowitz J (1986) Role of branched chain fatty acid precursors in regulating factor profile in the biosynthesis of A21978 C complex. J Antibiot 39:1483-1485